omburtamab

Y-mAbs' rare disease drug roundly rejected by FDA AdComm over weakness of single-arm trial
Fierce Biotech
Mon, 10/31/22 - 10:27 am
Y-mAbs Therapeutics
FDA
omburtamab
pediatric neuroblastoma
FDA Guidance Raises Concerns about Y-mAbs’ Neuroblastoma Treatment before Adcomm
BioSpace
Thu, 10/27/22 - 10:59 am
FDA
Y-mAbs Therapeutics
neuroblastoma
omburtamab
Y-mAbs pushes back re-submission of its neuroblastoma BLA to end of 2021
Endpoints
Wed, 06/23/21 - 10:41 am
Y-mAbs Therapeutics
neuroblastoma
FDA
omburtamab
FDA hands Y-mAbs refusal to file letter in one of its pediatric neuroblastoma programs
Endpoints
Tue, 10/6/20 - 10:54 am
Y-mAbs
FDA
neuroblastoma
omburtamab
RTF letters